Previous Page  19 / 38 Next Page
Information
Show Menu
Previous Page 19 / 38 Next Page
Page Background

EVEROLIMUS

TARGETED AGENTS

RADIANT-4 GASTROINTESTINAL TRACT AND UNKNOWN PRIMARY SUBGROUP

ANALYSIS (N=175)

PFS treatment effect for patient primary tumor site per central review

Singh S, et al. Neuroendocrinology 2017

mPFS GI = 13,1 vs 5,4 months (HR 0,56; 95%CI 0,37-0,84)

mPFS CUP = 13,6 vs 7,5 months (HR 0,60; 95%CI 0,24-1,51)